AnaptysBio's Upcoming Investor Conferences and Highlights
AnaptysBio's Upcoming Participation in Key Investor Conferences
AnaptysBio, Inc. (NASDAQ: ANAB), a biotechnology firm dedicated to pioneering innovative therapies for immunological diseases, has recently announced its exciting participation in several significant investor conferences. Daniel Faga, the esteemed president and CEO of AnaptysBio, along with the executive leadership team, will represent the company at these important events.
Investor Conferences Schedule
The company is set to engage actively in three major conferences:
TD Cowen 45th Annual Healthcare Conference
This event will feature a unique format including both a fireside chat and one-on-one meetings with investors. It is scheduled for March 4th, 2025, at 1:10 PM ET / 10:10 AM PT.
Leerink Partners 2025 Global Healthcare Conference
The second conference, taking place on March 11th, 2025, will also include a fireside chat along with one-on-one investor discussions, beginning at 10:40 AM ET / 7:40 AM PT.
Barclays 27th Annual Global Healthcare Conference
Lastly, on March 12th, AnaptysBio will participate in this conference featuring a presentation along with one-on-one investor engagements starting at 8:30 AM ET / 5:30 AM PT.
Access to Live Broadcasts
For those interested, live webcasts of the fireside chats and the presentation will be accessible through the investor section of the AnaptysBio website. Additionally, recordings of these webcasts will be available for at least 30 days post-event, ensuring investors do not miss out on these discussions.
About AnaptysBio
Founded on a mission to revolutionize treatments for autoimmune and inflammatory diseases, AnaptysBio focuses on developing groundbreaking immunology therapeutics. Their lead candidate, rosnilimab, targets PD-1+ T cells and is currently undergoing a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis. A diverse portfolio also includes promising candidates such as ANB033, a CD122 antagonist in Phase 1, and ANB101, which is entering Phase 1 as a BDCA2 modulator.
Furthermore, AnaptysBio has collaborated with GSK, discovering multiple therapeutic antibodies for immuno-oncology. This collaboration has produced innovative agents such as Jemperli (dostarlimab-gxly) and cobolimab (GSK4069889), indicating the company’s central role in advancing healthcare solutions.
Contact Information
For any inquiries or further engagement, please reach out to Nick Montemarano, Executive Director of Investor Relations, at 858-732-0178 or via the email provided.
Frequently Asked Questions
What is AnaptysBio known for?
AnaptysBio is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases.
When are the upcoming investor conferences?
The conferences are scheduled for March 4th, March 11th, and March 12th, 2025.
How can I access the webcasts of the conferences?
Live webcasts will be available on the investor section of the AnaptysBio website, with replays accessible for at least 30 days afterwards.
What are AnaptysBio's lead programs?
Their lead program is rosnilimab, targeting diseases like rheumatoid arthritis and ulcerative colitis, currently in clinical trials.
Who should I contact for more information?
Contact Nick Montemarano, the Executive Director of Investor Relations, for inquiries related to AnaptysBio.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
